Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.

Inclusion Criteria: * Participants must be male and have a pathological diagnosis of prostate cancer * Pathological diagnosis of prostate cancer must be confirmed and on file with CRA prior to study entry. * No treatment (surgery, radiation, or hormones) prior to study entry. * PSA between 2.0 and 10.0 ng/ml. * If PSA is \>10.0, patient must have been on Active Surveillance for 12 months prior to study initiation. * No known allergy to soy or soy products. * The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements). * Participant has not been on any previous GCP clinical trial. * Normal Chemistry values prior to study entry. Exclusion Criteria: * No pathological documentation of prostate cancer. * Prior treatment for prostate cancer. * PSA \>10.0 ng/ml but not on Active Surveillance for 12 months. * Allergy to soy or soy products. * Abnormal chemistry values.